Abstract
Therapeutic angiogenesis has received much attention for its potential benefits in ischemic vascular disorders. Recently, the clinical application of hepatocyte growth factor (HGF) for therapeutic angiogenesis has become well known. Statins have also been reported to promote angiogenesis and ameliorate ischemic conditions. In the present study, we examined the effects of fluvastatin on HGF-induced angiogenesis using a human umbilical vein endothelial cell (HUVEC)/normal human dermal fibroblast (NHDF) co-culture system. The HGF-induced angiogenesis was augmented by fluvastatin at low dose, but it was decreased at high dose. Although fluvastatin increased vascular endothelial growth factor expression in NHDFs, it was observed only at a high dose. Low-dose fluvastatin decreased the HGF-induced p38 mitogen-activated protein kinase (MAPK) phosphorylation (Thr-180/Tyr-182) and HUVEC apoptosis in the presence of HGF. SB203580, a p38 MAPK inhibitor, ameliorated anisomycin (a p38 MAPK activator)-induced angiogenesis suppression in the presence of HGF. Moreover, the augmentation of the HGF-induced angiogenesis by fluvastatin was abrogated by the p38 MAPK inhibitors, SB203580, SB202190, and FR167653. High-dose fluvastatin decreased Akt phosphorylation (Ser-473) and HUVEC proliferation, and it increased p27kip1 in HUVECs. Interestingly, fluvastatin decreased the mRNA expression of integrins and tissue inhibitor of metalloproteinases (TIMPs) in HUVECs. Our data therefore indicate that the stimulatory effects of low-dose fluvastatin on the HGF-induced angiogenesis are mediated by its inhibitory effects on p38 MAPK phosphorylation induced by HGF, which may result in the suppression of EC apoptosis. High-dose fluvastatin inhibits Akt phosphorylation and HUVEC proliferation, and it increases p27kip1, which may result in its inhibitory effects on angiogenesis. In addition, integrins and TIMPs are candidates for angiogenesis regulation by fluvastatin.
Similar content being viewed by others
Article PDF
References
Walsh DA : Pathophysiological mechanisms of angiogenesis. Adv Clin Chem 2007; 44: 187–221.
Takeshita S, Zheng LP, Brogi E, et al: Therapeutic angiogenesis. A single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model. J Clin Invest 1994; 93: 662–670.
Grant DS, Kleinman HK, Goldberg ID, et al: Scatter factor induces blood vessel formation in vivo. Proc Natl Acad Sci U S A 1993; 90: 1937–1941.
Morishita R, Aoki M, Hashiya N, et al: Safety evaluation of clinical gene therapy using hepatocyte growth factor to treat peripheral arterial disease. Hypertension 2004; 44: 203–209.
Pourati I, Kimmelstiel C, Rand W, Karas RH : Statin use is associated with enhanced collateralization of severely diseased coronary arteries. Am Heart J 2003; 146: 876–881.
Sata M, Nishimatsu H, Osuga J, et al: Statins augment collateral growth in response to ischemia but they do not promote cancer and atherosclerosis. Hypertension 2004; 43: 1214–1220.
Bishop ET, Bell GT, Bloor S, Broom IJ, Hendry NF, Wheatley DN : An in vitro model of angiogenesis: basic features. Angiogenesis 1999; 3: 335–344.
Saito A, Sugawara A, Uruno A, et al: All-trans retinoic acid induces in vitro angiogenesis via retinoic acid receptor: possible involvement of paracrine effects of endogenous vascular endothelial growth factor signaling. Endocrinology 2007; 148: 1412–1423.
Uruno A, Sugawara A, Kudo M, et al: Transcription suppression of thromboxane receptor gene expression by retinoids in vascular smooth muscle cells. Hypertens Res 2003; 26: 815–821.
Uruno A, Sugawara A, Kanatsuka H, et al: Hepatocyte growth factor stimulates nitric oxide production through endothelial nitric oxide synthase activation by the phosphoinositide 3-kinase/Akt pathway and possibly by mitogenactivated protein kinase kinase in vascular endothelial cells. Hypertens Res 2004; 27: 887–895.
Uruno A, Sugawara A, Kanatsuka H, et al: Upregulation of nitric oxide production in vascular endothelial cells by alltrans retinoic acid through the phosphoinositide 3-kinase/Akt pathway. Circulation 2005; 112: 727–736.
Matsumoto T, Turesson I, Book M, Gerwins P, Claesson-Welsh L : p38 MAP kinase negatively regulates endothelial cell survival, proliferation, and differentiation in FGF-2-stimulated angiogenesis. J Cell Biol 2002; 156: 149–160.
Nakagami H, Morishita R, Yamamoto K, et al: Phosphorylation of p38 mitogen-activated protein kinase downstream of bax–caspase-3 pathway leads to cell death induced by high D-glucose in human endothelial cells. Diabetes 2001; 50: 1472–1481.
Folkman J : Angiogenesis and apoptosis. Semin Cancer Biol 2003; 13: 159–167.
Liu W, Ahmad SA, Reinmuth N, et al: Endothelial cell survival and apoptosis in the tumor vasculature. Apoptosis 2000; 5: 323–328.
Davis GE, Senger DR : Endothelial extracellular matrix: biosynthesis, remodeling, and functions during vascular morphogenesis and neovessel stabilization. Circ Res 2005; 97: 1093–1107.
Raffetto JD, Khalil RA : Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease. Biochem Pharmacol 2008; 75: 346–359.
van Hinsbergh VW, Engelse MA, Quax PH : Pericellular proteases in angiogenesis and vasculogenesis. Arterioscler Thromb Vasc Biol 2006; 26: 716–728.
Weis M, Heeschen C, Glassford AJ, Cooke JP : Statins have biphasic effects on angiogenesis. Circulation 2002; 105: 739–745.
Urbich C, Dernbach E, Zeiher AM, Dimmeler S : Doubleedged role of statins in angiogenesis signaling. Circ Res 2002; 90: 737–744.
Kureishi Y, Luo Z, Shiojima I, et al: The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med 2000; 6: 1004–1010.
Brouet A, Sonveaux P, Dessy C, Moniotte S, Balligand JL, Feron O : Hsp90 and caveolin are key targets for the proangiogenic nitric oxide-mediated effects of statins. Circ Res 2001; 89: 866–873.
Frick M, Dulak J, Cisowski J, et al: Statins differentially regulate vascular endothelial growth factor synthesis in endothelial and vascular smooth muscle cells. Atherosclerosis 2003; 170: 229–236.
Wang CY, Liu PY, Liao JK : Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. Trends Mol Med 2008; 14: 37–44.
New L, Han J : The p38 MAP kinase pathway and its biological function. Trends Cardiovasc Med 1998; 8: 220–228.
McGillicuddy FC, O'Toole D, Hickey JA, Gallagher WM, Dawson KA, Keenan AK : TGF-beta1-induced thrombospondin-1 expression through the p38 MAPK pathway is abolished by fluvastatin in human coronary artery smooth muscle cells. Vascul Pharmacol 2006; 44: 469–475.
Siddiqui AJ, Gustafsson T, Fischer H, et al: Simvastatin enhances myocardial angiogenesis induced by vascular endothelial growth factor gene transfer. J Mol Cell Cardiol 2004; 37: 1235–1244.
Senokuchi T, Matsumura T, Sakai M, et al: Statins suppress oxidized low density lipoprotein-induced macrophage proliferation by inactivation of the small G protein p38 MAPK pathway. J Biol Chem 2005; 280: 6627–6633.
Ohashi N, Matsumori A, Furukawa Y, et al: Role of p38 mitogen-activated protein kinase in neointimal hyperplasia after vascular injury. Arterioscler Thromb Vasc Biol 2000; 20: 2521–2526.
Tojo A, Onozato ML, Kobayashi N, Goto A, Matsuoka H, Fujita T : Antioxidative effect of p38 mitogen-activated protein kinase inhibitor in the kidney of hypertensive rat. J Hypertens 2005; 23: 165–174.
Ikeuchi H, Kuroiwa T, Yamashita S, et al: Fluvastatin reduces renal fibroblast proliferation and production of type III collagen: therapeutic implications for tubulointerstitial fibrosis. Nephron Exp Nephrol 2004; 97: e115–e122.
Sivaprasad U, Abbas T, Dutta A : Differential efficacy of 3-hydroxy-3-methylglutaryl CoA reductase inhibitors on the cell cycle of prostate cancer cells. Mol Cancer Ther 2006; 5: 2310–2316.
Ferri N, Granata A, Pirola C, et al: Fluvastatin synergistically improves the antiproliferative effect of everolimus on rat smooth muscle cells by altering p27Kip1/cyclin E expression. Mol Pharmacol 2008; 74: 144–153.
Suzuki E, Nishimatsu H, Nagata D, et al: Constitutive activation of proto-oncogen protein p21 induces cell cycle arrest in the G1 phase in contact-inhibited vascular endothelial cells. Hypertens Res 2002; 25: 773–778.
Soker S, Gollamudi-Payne S, Fidder H, Charmahelli H, Klagsbrun M : Inhibition of vascular endothelial growth factor (VEGF)–induced endothelial cell proliferation by a peptide corresponding to the exon 7–encoded domain of VEGF165. J Biol Chem 1997; 272: 31582–31588.
Park HJ, Kong D, Iruela-Arispe L, Begley U, Tang D, Galper JB : 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors interfere with angiogenesis by inhibiting the geranylgeranylation of RhoA. Circ Res 2002; 91: 143–150.
Cai W, Chen X : Anti-angiogenic cancer therapy based on integrin alphavbeta3 antagonism. Anticancer Agents Med Chem 2006; 6: 407–428.
Ruegg C, Mariotti A : Vascular integrins: pleiotropic adhesion and signaling molecules in vascular homeostasis and angiogenesis. Cell Mol Life Sci 2003; 60: 1135–1157.
Higuchi M, Yasuda O, Kawamoto H, et al: Tissue inhibitor of metalloproteinase-3 deficiency inhibits blood pressure elevation and myocardial microvascular remodeling induced by chronic administration of Nω -nitro-L-arginine methyl ester in mice. Hypertens Res 2007; 30: 563–571.
Tan J, Hua Q, Xing X, Wen J, Liu R, Yang Z : Impact of the metalloproteinase-9/tissue inhibitor of metalloproteinase-1 system on large arterial stiffness in patients with essential hypertension. Hypertens Res 2007; 30: 959–963.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Uruno, A., Sugawara, A., Kudo, M. et al. Stimulatory Effects of Low-Dose 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitor Fluvatatin on Hepatocyte Growth Factor–Induced Angiogenesis: Involvement of p38 Mitogen-Activated Protein Kinase. Hypertens Res 31, 2085–2096 (2008). https://doi.org/10.1291/hypres.31.2085
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1291/hypres.31.2085
Keywords
This article is cited by
-
SIRT1 protects rat lung tissue against severe burn-induced remote ALI by attenuating the apoptosis of PMVECs via p38 MAPK signaling
Scientific Reports (2015)
-
Effects of AMP-Activated Protein Kinase in Cerebral Ischemia
Journal of Cerebral Blood Flow & Metabolism (2010)
-
Atorvastatin attenuates homocysteine-induced apoptosis in human umbilical vein endothelial cells via inhibiting NADPH oxidase-related oxidative stress-triggered p38MAPK signaling
Acta Pharmacologica Sinica (2009)